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Sir, 
Psoriatic arthritis (PsA) and psoriasis are closely related chronic inflammatory conditions 
leading to multi-tissue involvement. Polymorphisms in genes regulating Tumour Necrosis 
Factor alpha (TNFα) and the interleukin-23 and -17 axis (IL-23/17) are risk factors for both 
musculoskeletal and cutaneous phenotypes (1). Biological drugs are effective at the 
population level with significant overlap in clinical response between both cutaneous and 
musculoskeletal involvement. Unfortunately, some patients are refractory or intolerant to 
TNFα inhibitors (TNFi) or to biologics targeting the IL23/17 axis. The clinical practitioner may, 
on occasions, encounter affected individuals showing an excellent response from one tissue 
target, i.e. the skin, and incomplete response or even deterioration in others, such as the 
joints, the uvea or bowel. 
 
Here, we report six cases of long-lasting, complex PsA refractory and/or intolerant to several 
conventional synthetic and biologic disease-modifying anti-rheumatic drugs (csDMARDs and 
bDMARDs, respectively) who were exposed to a combination of an anti-IL-12/23 and a TNFi 
(Table 1). Dual targeting inhibition was considered in all cases as the TNFi worked on articular 
disease whereas the anti-IL12/23 only worked on skin. While combination therapy with 
differential cytokine inhibition mechanism showed some mild and subjective effects, it 
appeared to be associated with increased risk of infections. 
 
Beyond the advent of bDMARDs, the main therapeutic challenge in real life remains the lack 
of response-biomarkers to support stratified intervention. Because of this, and through a trial-
and-error approach, we found that some patients required dual inhibition of both TNFα and 
IL-12/23 to address disease activity at both the articular and the cutaneous level. This is 
suggestive of a TNFα-dependent arthropathy concomitant to an IL-23/17-axis-dependent 
psoriasis occurring in a subset of cases (2) (Figure 1). To our knowledge, there are only a few 
reports (3, 4) on the combination of bDMARDs in severe, refractory PsA. In our series, single-
targeted inhibition was inadequate to gain full control on disease activity, triggering the 
decision to trial a bDMARDs combination to selectively inhibit different cytokines. The 
rationale behind this is partly due to the synergistic effect of the modulation of the lymphoid 
stress surveillance response through IL-23/IL-17 axis (1). 
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The small number, diverse clinical features and uncontrolled nature of these cases and 
different drug combinations preclude any definitive scientific conclusions being drawn 
regarding evidence of clinical improvement. Further, in most cases toxicity precluded 
treatment continuation which also carried significant cost considerations. From a mechanistic 
viewpoint, although there appears to be strong overlap between TNFi and anti-IL12/23 at the 
population level, our findings suggest a differential role of TNFα and IL-23/17 pathways in the 
immunopathology of articular and cutaneous involvement in some psoriatic disease cases. 
Despite common tissue-specific factors in the skin and joint including Köebner responses 
(figure 1), some data suggest a differential involvement of pivotal innate immune cytokines, 
with the IL-23 pathway playing a greater role in the skin and TNFα pathway playing a greater 
role in the joints. We hypothesize that in some extreme cases such a polarisation may occur. 
Theoretical support for this comes from four strands. First, the IL-23 pathway genetics 
appears to be greater in psoriasis than in PsA(5). Secondly, animal models with IL-23 
dysregulation develop both psoriasiform skin inflammation and arthritis, whereas TNFα 
transgenic models develop enthesitis, synovitis and colitis but not skin disease(6). Human 
immunology studies, although limited in regards of the enthesis, point towards diverse and 
comparatively abundant IL-23R positive cells in the skin compared to the enthesis (7). 
Moreover, deficiency in IL-17 pathway leads to cutaneous fungal infection, but not arthritis, 
suggesting an important role of the IL-23/17 axis pathway in normal skin homeostasis. Finally, 
these and other case series (3, 4) consistently report on the effect of TNFi on arthritis and of 
IL-23 inhibitor on skin disease. No reports of bDMARDs combination therapy showing TNFi 
efficacy in skin disease and IL-23i efficacy for joint disease exist. Thus, despite common 
inciting factors including cutaneous or articular micro-damage and shared cytokine networks, 
there may be a differential innate immune cytokine hierarchy between skin and joints in a 
subset of cases. 
 
Drug development programmes confirmed the safety and efficacy of dual cytokine inhibition 
without superiority to conventional TNFi(8). Whereas this may apply to the population level, 
the need remains for single molecules with safe, dual targeting properties to be developed in 
PsA and psoriasis cases showing divergent therapy responses. 
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Key message 
We hypothesize a differential cutaneous/articular cytokine hierarchy in a subset of psoriatic 
disease cases. 
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Table 1. Main clinical characteristics and treatment history of the clinical series.  
 
 Case 1 
41 year old 
female 
Case 2 
50 year old 
female 
Case 3 
63 year old 
female 
Case 4 
32 year old 
male 
Case 5 
49 year old 
female 
Case 6 
45 year old 
male 
Primary 
disease phenotype 
(duration to 
presentation) 
Polyarticular (13 years)  Polyarticular (12 years) Axial and polyarticular 
(20 years) 
Polyarticular (17 years) Polyarticular (24 
years) 
Axial and 
oligoarticular (20 
years) 
Psoriasis 
(phenotype)  
Plaque Plaque Flexural Plaque Plaque Plaque, 
“paradoxical”* 
Other extra-
articular 
manifestations 
None Uveitis Uveitis; 
Crohn’s disease 
None Uveitis Uveitis 
(likely secondary to 
ETN**) 
SpA-related 
characteristics 
  HLA-B27+ve HLA-B27+ve 
Family history of AS 
HLA-B27+ve  
Co-morbidities Morbid obesity  Obesity; 
Essential arterial 
hypertension 
Bronchial asthma; 
COPD; 
Liver cirrhosis 
Dyslipidaemia; 
Essential arterial 
hypertension 
Obesity; 
Essential arterial 
hypertension 
None 
Previous 
csDMARDs 
SSZ, MTX, HCQ, AZT, 
LEF 
SSZ, MTX AZT (for bowel) MTX Tacrolimus, MTX, 
Cyclosporin A, 
oral steroids 
MTX, MMF, 
Tacrolimus, oral 
steroids 
Previous 
bDMARDs 
ADA (2006) (for 
joints): non-specific 
neurologic side effects 
(MS excluded) 
INF: 2nd NR initially 
effective on skin and 
eyes; 
ADA: 1NR; 
INF (2004) (for joints): 
2nd NR; 
ADA (2012) (for joints 
and skin)  2nd NR on 
both joints and skin; 
INF (for joints): 
2nd NR; 
GOL (for joints): 
2nd NR 
**ETN: stopped 
due to 
development of 
uveitis; 
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GOL: 2nd NR ; 
UST (for skin) - LEF 
added for joints at this 
point, but stopped in 
2014 (1NR) 
ETN (2005-8) (for 
joints): stopped due to 
uveitis flare 
INF (for joints and skin): 
effective on joints, 
2 nd NR in skin 
 *ADA: developed 
Psoriasis; 
GOL: 2nd NR; 
INF: 2NR 
Most recent 
bDMARD 
UST (excellent control 
of skin, but not of 
joints) 
UST (no control of 
joints) 
 
ADA (2008-2017) (for 
bowel and joints), led to 
new flare of Psoriasis 
UST (2013) (for skin) UST helped skin 
but not joints 
CZP prescribed for 
joints 
Biologic co-
prescribed and 
purpose 
ETN successfully 
added (Feb 2014) to 
UST to regain control 
of joints 
CZP (Jan 2015) 
successfully added to 
UST to regain control of 
joints 
UST (2016) successfully 
added to ADA to regain 
control of skin 
ETN (2015) added to 
UST to regain control of 
articular disease 
First ETN added 
to UST to regain 
control of 
articular disease 
(not tolerated 
due to uveitis); 
Then UST+ADA 
(not effective on 
joints); 
Then UST+CTZ 
UST added onto 
CZP to regain 
control of skin 
Overall duration of 
exposure to 
bDMARDs 
combination 
15 months 6 months 3 months 24 months 15 months 12 months 
Reason for 
discontinuation of 
bDMARDs 
combination  
Developed severe skin 
infection 
Discontinued because 
of 2 chest infections 
Respiratory failure with 
recurrent chest 
infections 
Developed chest 
sarcoidosis mediastinal 
and hilar 
lymphadenopathy 
2nd NR (joints) 
followed by bout 
of uveitis  
Lack of significant 
response from skin 
and joints 
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Therapy 
subsequent to 
bDMARDs 
combination 
 APR started in October 
2015, regained control 
of synovitis and skin 
Chronic pain syndrome 
  Ixekizumab 
(dramatic skin 
improvement, 
mild articular 
improvement) 
SEC (Good 
improvement in 
skin only) 
PsA = psoriatic arthritis; AS = ankylosing spondylitis; SpA = Spondyloarthritis; COPD = chronic obstructive pulmonary disease; bDMARDs = biologic disease-modifying 
anti-rheumatic drugs; sDMARDs = synthetic disease-modifying anti-rheumatic drugs; SSZ = sulphasalazine; MTX = methotrexate; HCQ = hydroxychloroquine; AZT = 
azathioprine; MMF = mofetil mycophenolate; ADA = adalimumab; MS = multiple sclerosis; INF = infliximab; 2nd NR = secondary non-response; 1NR = primary non-
response; GOL = golimumab; ETN = etanercept; UST = ustekinumab; CZP = certolizumab pegol; APR = apremilast; SEC = secukinumab. 
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Figure 1 
 
 
Legend 
Suggestions for a differential involvement of innate immune cytokines in psoriatic disease. The IL-23 pathway may play a greater role in the skin, 
while the TNFα pathway may retain a greater role in the joints. 
